Heartflow, Inc.
37.52-0.78 (-2.04%)
Oct 29, 4:00:01 PM EDT · NasdaqGS · HTFL · USD
Key Stats
Market Cap
3.13BP/E (TTM)
-Basic EPS (TTM)
-1.16Dividend Yield
0%Recent Filings
10-Q
Q2 FY2025 results
Heartflow's Q2 FY2025 revenue surged 40% y/y to $43.4M, driven by 47% higher case volumes, while YTD revenue climbed 39% y/y to $80.6M; gross margin dipped to 75% from 77% y/y amid production team investments, yet operating loss narrowed 3% y/y to $13.7M as R&D and SG&A scaled with growth. Diluted EPS improved to -$1.46 from -$4.66 y/y, reconciling to 6.3M weighted shares with no anti-dilution flagged. Cash rose to $80.2M, with FCF not disclosed in the 10-Q; total debt stood at $182.4M including $114.1M term loan (due 2028 at ~15.2%) and $68.3M convertible notes (due 2029 at 7%). Post-period, the August 2025 IPO raised ~$332.8M net, converting notes to equity and repaying debt. Competition from traditional CAD diagnostics persists.
8-K
HeartFlow's preliminary Q2 results
HeartFlow disclosed preliminary Q2 2025 results at the Morgan Stanley Global Healthcare Conference, showing revenue of $43.4 million, a 75.5% gross margin, and operating expenses of $46.5 million, alongside $80.2 million in cash as of June 30. The recent IPO added $333.0 million in net proceeds, enabling full repayment of $114.1 million in debt plus interest during Q3. These figures remain unaudited and subject to change upon 10-Q filing.
8-K
Heartflow terminates Hayfin debt
Heartflow, Inc. prepaid its entire $60.1 million Hayfin credit facility plus $1.0 million accrued interest on August 22, 2025, terminating the agreement without fees. This clears all debt obligations from the June 2024 deal, amended in January 2025. Debt-free now. The move strengthens the balance sheet amid its emerging growth phase.
8-K
Heartflow IPO closes
Heartflow completed its initial public offering on August 11, 2025, selling 19,166,667 shares of common stock at $19.00 per share, generating gross proceeds of approximately $364 million before expenses. The IPO triggered effectiveness of the company's amended and restated certificate of incorporation and bylaws, aligning governance with public company standards. Funds bolster operational growth. No risks detailed.
IPO
Website
Employees
Sector
Industry
AIFF
Firefly Neuroscience, Inc.
1.92+0.00
AVR
Anteris Technologies Global Cor
4.40-0.42
BEAT
Heartbeam, Inc.
1.60+0.01
BFLY
Butterfly Network, Inc.
2.15-0.06
EW
Edwards Lifesciences Corporatio
82.69+0.50
HSCS
HeartSciences Inc.
2.97-0.19
HTCR
Heartcore Enterprises, Inc.
0.75-0.01
HYDTF
Hydreight Technologies Inc
3.28-0.09
NGHLF
Nightingale Health Oyj
1.75+0.00
OHCFF
LIGHT AI INC.
0.12-0.00